3P5B
| The structure of the LDLR/PCSK9 complex reveals the receptor in an extended conformation | Descriptor: | CALCIUM ION, Low density lipoprotein receptor variant, Proprotein convertase subtilisin/kexin type 9 | Authors: | Lo Surdo, P, Bottomley, M.J, Calzetta, A, Settembre, E.C, Cirillo, A, Pandit, S, Ni, Y, Hubbard, B, Sitlani, A, Carfi, A. | Deposit date: | 2010-10-08 | Release date: | 2011-10-26 | Last modified: | 2017-11-08 | Method: | X-RAY DIFFRACTION (3.3 Å) | Cite: | Mechanistic implications for LDL receptor degradation from the PCSK9/LDLR structure at neutral pH. Embo Rep., 12, 2011
|
|
3P5C
| The structure of the LDLR/PCSK9 complex reveals the receptor in an extended conformation | Descriptor: | CALCIUM ION, Low density lipoprotein receptor variant, Proprotein convertase subtilisin/kexin type 9 | Authors: | Lo Surdo, P, Bottomley, M.J, Calzetta, A, Settembre, E.C, Cirillo, A, Pandit, S, Ni, Y, Hubbard, B, Sitlani, A, Carfi, A. | Deposit date: | 2010-10-08 | Release date: | 2011-10-26 | Last modified: | 2024-01-17 | Method: | X-RAY DIFFRACTION (4.2 Å) | Cite: | Mechanistic implications for LDL receptor degradation from the PCSK9/LDLR structure at neutral pH. Embo Rep., 12, 2011
|
|
3SN7
| Highly Potent, Selective, and Orally Active Phosphodiestarase 10A Inhibitors | Descriptor: | 8-fluoro-6-methoxy-3,4-dimethyl-1-(3-methylpyridin-4-yl)imidazo[1,5-a]quinoxaline, CHLORIDE ION, MAGNESIUM ION, ... | Authors: | Parris, K.D. | Deposit date: | 2011-06-28 | Release date: | 2011-10-26 | Last modified: | 2024-02-28 | Method: | X-RAY DIFFRACTION (1.82 Å) | Cite: | Highly Potent, Selective, and Orally Active Phosphodiesterase 10A Inhibitors. J.Med.Chem., 54, 2011
|
|
7V97
| Arsenic-bound p53 DNA-binding domain mutant V272M | Descriptor: | ARSENIC, Cellular tumor antigen p53, ZINC ION | Authors: | Lu, M, Xing, Y.F, Wang, Z.Y, Ni, Y, Song, H.X. | Deposit date: | 2021-08-24 | Release date: | 2022-08-31 | Last modified: | 2023-11-29 | Method: | X-RAY DIFFRACTION (2.02 Å) | Cite: | Diverse rescue potencies of p53 mutations to ATO are predetermined by intrinsic mutational properties. Sci Transl Med, 15, 2023
|
|